FDA panel recommends approval for Vertex cystic fibrosis drug
Correction: An earlier version of this story mischaracterized the FDA's approval process today. The FDA has not yet approved Vertex's drug; an FDA advisory panel has recommended its approval.
The Food and Drug Administration's advisory committee has recommended that the FDA approve a new drug from Vertex Pharmaceuticals, which has the potential to help treat an additional 8,500 patients with cystic fibrosis.
The drug, Orkambi, has the potential to make the 26-year-old Boston-based drugmaker (Nasdaq:…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Jessica Bartlett Source Type: news
More News: American Health | Cystic Fibrosis | Food and Drug Administration (FDA) | Health | Health Management